300294 博雅生物
已收盘 02-27 15:00:00
资讯
新帖
简况
博雅生物（300294）披露公司董事暨总裁辞任公告，2月27日股价下跌0.09%
证券之星 · 02-27 17:17
博雅生物（300294）披露公司董事暨总裁辞任公告，2月27日股价下跌0.09%
博雅生物(300294.SZ)董事、总裁任辉辞任
智通财经 · 02-27 07:46
博雅生物(300294.SZ)董事、总裁任辉辞任
博雅生物：公司共计拥有2张血液制品生产牌照、21个单采血浆站（含绿十字旗下4个）
证券之星 · 02-25
博雅生物：公司共计拥有2张血液制品生产牌照、21个单采血浆站（含绿十字旗下4个）
博雅生物(300294.SZ)：人凝血因子Ⅸ药物临床试验获批准
智通财经 · 02-24
博雅生物(300294.SZ)：人凝血因子Ⅸ药物临床试验获批准
博雅生物：控股股东华润医药累计增持公司股份6,050,900股
证券之星 · 02-13
博雅生物：控股股东华润医药累计增持公司股份6,050,900股
博雅生物：公司已确定聚焦血液制品的发展战略
证券之星 · 02-12
博雅生物：公司已确定聚焦血液制品的发展战略
博雅生物：公司经理层的薪酬由基本年薪、年度绩效奖金、任期激励、津贴补贴和福利等组成
证券之星 · 02-11
博雅生物：公司经理层的薪酬由基本年薪、年度绩效奖金、任期激励、津贴补贴和福利等组成
博雅生物：做强做优做大华润大健康板块唯一的血液制品平台
证券之星 · 02-10
博雅生物：做强做优做大华润大健康板块唯一的血液制品平台
博雅生物：在华润集团及华润医药等股东的支持下，公司将继续致力于成为世界一流的血液制品企业
证券之星 · 02-09
博雅生物：在华润集团及华润医药等股东的支持下，公司将继续致力于成为世界一流的血液制品企业
博雅生物：控股股东华润医药累计增持公司股份6,050,900股
证券之星 · 02-04
博雅生物：控股股东华润医药累计增持公司股份6,050,900股
博雅生物：静注人免疫球蛋白工艺变更提升收得率
证券之星 · 02-02
博雅生物：静注人免疫球蛋白工艺变更提升收得率
港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响
智通财经 · 02-02
港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响
股市必读：博雅生物（300294）预计2025年全年营业收入19.08亿元至21.69亿元
证券之星 · 02-02
股市必读：博雅生物（300294）预计2025年全年营业收入19.08亿元至21.69亿元
博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%
智通财经 · 01-30
博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%
华润医药(03320)：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降
智通财经 · 01-30
华润医药(03320)：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降
华润医药旗下博雅生物预计全年营业收入增长10%至25%
美股速递 · 01-30
华润医药旗下博雅生物预计全年营业收入增长10%至25%
华润医药预计博雅生物全年归母净利润区间为1.05亿元至1.365亿元
美股速递 · 01-30
华润医药预计博雅生物全年归母净利润区间为1.05亿元至1.365亿元
股市必读：博雅生物（300294）1月23日董秘有最新回复
证券之星 · 01-26
股市必读：博雅生物（300294）1月23日董秘有最新回复
博雅生物：公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响
证券之星 · 01-23
博雅生物：公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响
股市必读：博雅生物（300294）1月16日董秘有最新回复
证券之星 · 01-19
股市必读：博雅生物（300294）1月16日董秘有最新回复
加载更多
公司概况
公司名称：
华润博雅生物制药集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-03-08
主营业务：
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是白蛋白、免疫球蛋白和凝血因子。公司先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格：
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":22.25,"timestamp":1772175819000,"preClose":22.27,"halted":0,"volume":2205307,"delay":0,"changeRate":-0.0009,"floatShares":504000000,"shares":504000000,"eps":0.649,"marketStatus":"已收盘","change":-0.02,"latestTime":"02-27 15:00:00","open":22.25,"high":22.31,"low":22.15,"amount":49045300,"amplitude":0.0072,"askPrice":22.26,"askSize":356,"bidPrice":22.25,"bidSize":48,"shortable":0,"etf":0,"ttmEps":0.649,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":22.27,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":24.5,"lowLimit":20.04,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.46,"roa":"--","peRate":34.283513,"roe":"4.5%","epsLYR":0.79,"committee":0.180807,"marketValue":11220000000,"turnoverRate":0.0044,"status":1,"floatMarketCap":11220000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2614835576","title":"博雅生物（300294）披露公司董事暨总裁辞任公告，2月27日股价下跌0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835576","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835576?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:17","pubTimestamp":1772183845,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，博雅生物报收于22.25元，较前一交易日下跌0.09%，最新总市值为112.2亿元。博雅生物于近日披露《关于公司董事暨总裁辞任的公告》。公告显示，华润博雅生物制药集团股份有限公司于2026年2月26日收到董事、总裁任辉先生的书面辞任报告，其因工作变动原因申请辞去公司第八届董事会董事、战略与ESG委员会委员、总裁及法定代表人职务，辞任后不再担任公司任何职务。截至公告日，任辉先生未持有公司股份，无应履行未履行承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028549.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","300294","BK0239"],"gpt_icon":0},{"id":"2614070028","title":"博雅生物(300294.SZ)董事、总裁任辉辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2614070028","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614070028?lang=zh_cn&edition=full","pubTime":"2026-02-27 07:46","pubTimestamp":1772149600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)发布公告，公司董事会于2026年2月26日收到公司董事、总裁任辉先生递交的书面《辞任报告》，任辉先生因工作变动原因申请辞去公司第八届董事会董事、战略与ESG委员会委员及总裁、法定代表人的职务，辞任后将不再担任公司任何职务。任辉先生的辞任不会影响公司的正常生产运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","BK0046","BK0239","BK0197"],"gpt_icon":0},{"id":"2614595087","title":"博雅生物：公司共计拥有2张血液制品生产牌照、21个单采血浆站（含绿十字旗下4个）","url":"https://stock-news.laohu8.com/highlight/detail?id=2614595087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614595087?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:18","pubTimestamp":1772025495,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)02月25日在投资者关系平台上答复投资者关心的问题。投资者提问：华润集团是否拥有血站资源？是否会注入博雅？谢谢介绍博雅生物回复：您好，感谢您对本公司的关注。华润博雅生物系华润大健康板块的血液制品平台，截至目前，公司共计拥有2张血液制品生产牌照、21个单采血浆站（含绿十字旗下4个）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500037253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300294"],"gpt_icon":0},{"id":"2613796451","title":"博雅生物(300294.SZ)：人凝血因子Ⅸ药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613796451","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613796451?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:55","pubTimestamp":1771923345,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)公告，公司收到国家药品监督管理局核准签发的人凝血因子Ⅸ《药物临床试验批准通知书》，获同意开展用于凝血因子Ⅸ缺乏症(血友病B)患者的出血治疗的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300294","BK0197","BK0046"],"gpt_icon":0},{"id":"2611526881","title":"博雅生物：控股股东华润医药累计增持公司股份6,050,900股","url":"https://stock-news.laohu8.com/highlight/detail?id=2611526881","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611526881?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:51","pubTimestamp":1770987092,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)02月12日在投资者关系平台上答复投资者关心的问题。投资者提问：华润入主多少年则博雅跌了多少年，实控人为什么不增持？博雅生物回复：答：您好，感谢您对本公司的关注。公司控股股东华润医药于2024年11月8日-2025年5月7日累计增持公司股份6,050,900股（占公司总股本1.2000%）。截至目前，除上述增持外，公司未收到控股股东关于增持公司股份计划的通知，如有上述事项，公司将及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300035898.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1570","BK0046","BK0197","03320","BK0239","300294","BK1191"],"gpt_icon":0},{"id":"2610926191","title":"博雅生物：公司已确定聚焦血液制品的发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2610926191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610926191?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:48","pubTimestamp":1770900500,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：新百药业的处置或者剥离，有具体的时间表吗？博雅生物回复：您好，感谢您对本公司的关注。公司已确定聚焦血液制品的发展战略，对于非血液制品业务将适时进行处置或剥离，若有相关进展，公司将及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200037491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","BK0046","300294"],"gpt_icon":0},{"id":"2610980753","title":"博雅生物：公司经理层的薪酬由基本年薪、年度绩效奖金、任期激励、津贴补贴和福利等组成","url":"https://stock-news.laohu8.com/highlight/detail?id=2610980753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610980753?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:33","pubTimestamp":1770802389,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：公司经营陷入困境亏损，公司高管为什么不减薪？公司没有基本的考核制度吗？博雅生物回复：您好，感谢您对本公司的关注。公司经理层的薪酬由基本年薪、年度绩效奖金、任期激励、津贴补贴和福利等组成，其中年度绩效奖金、任期激励为浮动薪酬。薪酬水平已参考行业、实际经营情况等因素。关于公司经理层的薪酬机制及薪酬结构等请参阅《公司经理层成员薪酬管理办法》。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100027934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0197","300294"],"gpt_icon":0},{"id":"2610364017","title":"博雅生物：做强做优做大华润大健康板块唯一的血液制品平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610364017?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:48","pubTimestamp":1770727703,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物02月09日在投资者关系平台上答复投资者关心的问题。华润博雅生物锚定“做强做优做大华润大健康板块唯一的血液制品平台”核心定位，坚定践行华润“1246”模式，以“四个重塑”为抓手，在复杂多变的市场环境中攻坚克难。自2021年华润医药控股以来，公司在原料血浆端拓展、终端掌控、研发创新、国际化等方面均保持稳健发展，具体经营情况及财务状况请参阅公司公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"gpt_icon":0},{"id":"2610164633","title":"博雅生物：在华润集团及华润医药等股东的支持下，公司将继续致力于成为世界一流的血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2610164633","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610164633?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:18","pubTimestamp":1770628696,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物02月09日在投资者关系平台上答复投资者关心的问题。华润集团成为公司实际控制人后，在新浆站申请、资源嫁接、浆站运营等方面给予大力支持。在华润集团及华润医药等股东的支持下，公司将继续致力于成为世界一流的血液制品企业，不断推动行业健康发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900021764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK1570","300294","BK1191","BK0197","03320"],"gpt_icon":0},{"id":"2608336149","title":"博雅生物：控股股东华润医药累计增持公司股份6,050,900股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336149","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608336149?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:52","pubTimestamp":1770209553,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物02月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：公司股价长期低迷近5年，严重偏离市场。特别从9.24行情以来，创业板指涨幅超20%，而公司股价跌幅超20%。公司股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400039509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1570","BK0046","BK0197","03320","BK0239","300294","BK1191"],"gpt_icon":0},{"id":"2608854139","title":"博雅生物：静注人免疫球蛋白工艺变更提升收得率","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854139","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854139?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:12","pubTimestamp":1770023534,"startTime":"0","endTime":"0","summary":"投资者提问：公司公告显示绿十字（中国）5%静丙已完成二次层析工艺变更并获批。本次静注人免疫球蛋白生产工艺变更的主要内容是由辛酸盐沉淀和二次层析法代替原工艺的离心沉淀法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200024504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"gpt_icon":0},{"id":"2608713839","title":"港股异动 | 华润医药(03320)跌近3% 华润博雅生物预期年度归母净利同比大幅下降 血液制品业务受多因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2608713839","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608713839?lang=zh_cn&edition=full","pubTime":"2026-02-02 11:37","pubTimestamp":1770003478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华润医药跌近3%，截至发稿，跌1.98%，报4.46港元，成交2516.48万港元。公告称，华润博雅生物的血液制品业务受到扩大集采、DRG/DIP改革、医疗保险费用控制及重点监管合理用药等因素影响，导致临床处方减少以及需求下降，与此同时，市场竞争持续加剧，导致报告期内华润博雅生物血液制品业务的毛利率同比下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0239","BK1570","BK0197","VT","BK0046","BK4585","300294","BK4588","03320"],"gpt_icon":0},{"id":"2608889566","title":"股市必读：博雅生物（300294）预计2025年全年营业收入19.08亿元至21.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889566","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889566?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:17","pubTimestamp":1769973430,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，博雅生物报收于22.95元，下跌0.86%，换手率1.18%，成交量5.96万手，成交额1.37亿元。博雅生物发布业绩预告，预计2025年全年归属净利润盈利1.05亿元至1.36亿元。公司2025年度业绩预告华润博雅生物制药集团股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为10,500.00万元至13,650.00万元，比上年同期下降65.62%至73.55%；扣除非经常性损益后的净利润为-1,500.00万元至-750.00万元，同比下降102.49%至104.97%。营业收入预计为190,839.48万元至216,863.05万元，同比增长10.00%至25.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"gpt_icon":0},{"id":"2607014663","title":"博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607014663","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607014663?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:07","pubTimestamp":1769771249,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博雅生物(300294.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%;扣除非经常性损益后的净亏损750万元至1500万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"博雅生物(300294.SZ)发预减，预计2025年度归母净利润1.05亿元至1.37亿元，同比下降65.62%至73.55%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294"],"gpt_icon":0},{"id":"2607163500","title":"华润医药(03320)：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2607163500","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607163500?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:59","pubTimestamp":1769767199,"startTime":"0","endTime":"0","summary":"报告期内，华润博雅生物预期非经常性损益对净利润的影响约为人民币1.2亿元，主要受政府补助、出售资产及财富管理收入等因素影响。截至2024年12月31日止年度，非经常性损益为人民币9500万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","03320"],"gpt_icon":0},{"id":"1196965835","title":"华润医药旗下博雅生物预计全年营业收入增长10%至25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1196965835","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196965835?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:58","pubTimestamp":1769767091,"startTime":"0","endTime":"0","summary":"华润医药集团（股票代码：03320）旗下成员企业博雅生物（股票代码：300294）近日发布业绩预告，预计其本财年营业收入将实现同比增长，增幅区间在10%至25%之间。这一积极预期反映了公司核心业务的稳健发展态势与良好的市场表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK1191","BK1570","BK0197","300294","BK0239","03320"],"gpt_icon":0},{"id":"1190881177","title":"华润医药预计博雅生物全年归母净利润区间为1.05亿元至1.365亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190881177","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190881177?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:57","pubTimestamp":1769767030,"startTime":"0","endTime":"0","summary":"华润医药集团发布业绩预告，其旗下子公司博雅生物制药集团预计全年归属于母公司股东的净利润将达到1.05亿元至1.365亿元。这一业绩指引反映了公司在血液制品等核心业务领域的稳健表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0197","BK0046","BK1570","03320","BK1191","BK0239","300294"],"gpt_icon":0},{"id":"2606263550","title":"股市必读：博雅生物（300294）1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606263550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606263550?lang=zh_cn&edition=full","pubTime":"2026-01-26 01:52","pubTimestamp":1769363533,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，博雅生物报收于23.17元，上涨0.74%，换手率1.11%，成交量5.58万手，成交额1.29亿元。董秘最新回复投资者： 请问，截至1月20日，公司股东账户数量多少？公司2026年1月20日含信用账户合并名册的股东人数为30,593户。贵公司作为一个国企，怎么二级市场表现都是几年新低，到底是什么原因董秘： 您好，感谢您对本公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600000812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0197","BK0046"],"gpt_icon":0},{"id":"2605847393","title":"博雅生物：公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2605847393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605847393?lang=zh_cn&edition=full","pubTime":"2026-01-23 17:18","pubTimestamp":1769159889,"startTime":"0","endTime":"0","summary":"证券之星消息，博雅生物(300294)01月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！贵公司作为一个国企，怎么二级市场表现都是几年新低，到底是什么原因博雅生物回复：您好，感谢您对本公司的关注。公司二级市场股票价格受宏观环境、市场政策、投资者风险偏好等因素影响。公司经营情况请参与公司定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300028372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"gpt_icon":0},{"id":"2604483974","title":"股市必读：博雅生物（300294）1月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604483974","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604483974?lang=zh_cn&edition=full","pubTime":"2026-01-19 03:29","pubTimestamp":1768764548,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，博雅生物报收于23.18元，下跌0.43%，换手率0.69%，成交量3.5万手，成交额8127.03万元。董秘最新回复投资者： 公司近期表示，广东联盟集采价格已落地，但行业利润端普遍承压。当日关注点来自交易信息汇总：1月16日主力资金净流出406.68万元，显示主力短期减持动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900001280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0197","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772298647162,"stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":-0.0301},{"period":"3month","weight":-0.0639},{"period":"6month","weight":-0.1588},{"period":"1year","weight":-0.1878},{"period":"ytd","weight":-0.0155}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31595人(较上一季度减少0.27%)","perCapita":"15959股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是白蛋白、免疫球蛋白和凝血因子。公司先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项，拥有各类专利200余项，多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}